Licartin

Drug Overview

Licartin (also known by its chemical name, Iodine-131 metuximab injection) is a specialized “Smart Drug” used primarily in the treatment of advanced liver cancer. It belongs to a modern class of cancer treatments called Radioimmunotherapy. This therapy combines the precision of the immune system with the power of radiation to destroy cancer cells from the inside out.

For patients and healthcare providers, Licartin represents a highly targeted approach. Unlike standard radiation that beams through the whole body, Licartin travels through the bloodstream or is injected directly into the liver’s blood supply. It acts like a “guided missile” that seeks out a specific marker on liver cancer cells, delivering a lethal dose of radiation specifically to the tumor while minimizing damage to healthy surrounding tissues.

• Generic Name: Iodine [131I] metuximab
• US Brand Names: None (Currently investigational in the US; approved in other international markets).
• Drug Class: Radioimmunotherapeutic; Monoclonal Antibody Conjugate.
• Route of Administration: Intravenous (IV) or Hepatic Arterial Infusion (HAI).
• FDA Approval Status: Investigational (Not yet FDA approved for general use in the US).

What Is It and How Does It Work? (Mechanism of Action)

To understand how Licartin works, imagine a lock and a key. The cancer cells have a specific “lock” on their surface, and Licartin is the “key” designed to find it.

At the molecular level, Licartin follows a three-step process to destroy cancer:

1. The Seeker (Metuximab): The core of the drug is a monoclonal antibody called Metuximab. This antibody is specifically engineered to target a protein called HAb18G/CD147. This protein is found in very high amounts on the surface of Hepatocellular Carcinoma (HCC) cells but is rarely found on healthy liver cells.
2. The Payload (Iodine-131): Attached to the antibody is a radioactive isotope called Iodine-131. This isotope is a “powerhouse” that emits beta radiation and gamma rays.
3. The Attack: Once the Metuximab “key” locks onto the CD147 “lock” on the cancer cell, the cell pulls the drug inside. The Iodine-131 then releases its radiation. The beta particles travel only a short distance (a few millimeters), causing “Double-Strand Breaks” in the cancer cell’s DNA. This prevents the cell from dividing and forces it to die (apoptosis).

Because the radiation only travels a very short distance, the surrounding healthy liver cells are protected from the “blast radius” of the treatment.

FDA-Approved Clinical Indications

Licartin is currently utilized in international markets and clinical trials for the following conditions:

Oncological Uses

• Hepatocellular Carcinoma (HCC): Specifically for patients with advanced liver cancer that cannot be removed by surgery or for those whose cancer has returned after a transplant.
• Prevention of Recurrence: Used after liver surgery (resection) to kill any microscopic cancer cells left behind.

Non-Oncological Uses

• There are currently no non-oncological uses for this medication.

Dosage and Administration Protocols

Licartin is administered in a hospital setting by a team specializing in nuclear medicine and oncology.

Dose Adjustments:

• Hepatic Insufficiency: Patients with severe liver failure (Child-Pugh Class C) are generally not candidates for this treatment.
• Renal Insufficiency: Because the radioactivity is cleared through the kidneys, patients with poor kidney function require dose reductions to prevent radiation buildup.

Clinical Efficacy and Research Results

Clinical data from studies conducted between 2020 and 2025 have shown that Licartin can significantly improve survival for liver cancer patients.

• Survival Rates: In a major clinical trial, patients who received Licartin after liver surgery had a 5-year survival rate of approximately 58%, compared to 43% in the group that only had surgery.
• Recurrence Prevention: Numerical data shows that Licartin reduces the risk of the cancer coming back by roughly 25% to 30% in the first two years after treatment.
• Tumor Shrinkage: In advanced cases where surgery wasn’t possible, Licartin led to “Objective Responses” (tumor shrinkage) in about 15% to 20% of patients, which is significant for late-stage liver disease.

Safety Profile and Side Effects

Black Box Warning:

None. (However, strict Radiation Safety Precautions are required following administration).

Common Side Effects (>10%)

• Fatigue: Feeling unusually tired for several days.
• Fever: A mild rise in temperature shortly after infusion.
• Nausea: Mild stomach upset.
• Temporary Drop in Blood Counts: Lower white blood cells or platelets.

Serious Adverse Events

• Myelosuppression: A significant drop in blood counts that may require a transfusion.
• Radiation-Induced Liver Disease (RILD): Inflammation of the liver due to radiation.
• Allergic Reactions: Rare instances of itching or trouble breathing during the infusion.

Management Strategies

• Hydration: Patients must drink plenty of water to help “flush” the radioactive materials out of their system.
• Monitoring: Weekly blood tests are required for at least one month after treatment to check blood cell levels.

Research Areas

Licartin is currently being studied in combination with Immunotherapy (such as Checkpoint Inhibitors). Scientists believe that as Licartin kills cancer cells and makes them burst, the immune system “wakes up” and becomes better at finding other hidden tumors. There is also early research into using the CD147 targeting technology of Licartin to deliver Stem Cell signals to damaged liver tissue, though this is currently in the experimental laboratory phase.

Patient Management and Practical Recommendations

Pre-treatment Tests to be Performed

• CD147 Expression Test: A biopsy to confirm the tumor has the right “lock” for the drug.
• Liver Function Tests (ALT, AST, Bilirubin).
• Kidney Function Test (Creatinine/GFR).
• Pregnancy Test: Radiation is highly harmful to an unborn baby.

Precautions During Treatment

• Radiation Safety: For 3 to 7 days after treatment, you will be “radioactive.” You must avoid close contact with pregnant women and small children.
• Toilet Hygiene: You must flush the toilet twice after use and wash your hands thoroughly, as the drug leaves the body through urine.

“Do’s and Don’ts” List

• Do drink at least 2 liters of water daily for the first week after treatment.
• Do tell your doctor if you have ever had an allergic reaction to iodine (such as CT scan contrast).
• Don’t sleep in the same bed as another person for the first 5 days after treatment.
• Don’t assume you are “contagious”—the radiation is only inside you, but it can be found in your body fluids.

Legal Disclaimer

Standard medical information disclaimer: This guide is for informational purposes only and does not constitute medical advice. Licartin is a specialized radiopharmaceutical. Always consult with a licensed oncologist and nuclear medicine specialist regarding your specific diagnosis and treatment options. This content reflects data available as of early 2026.